Canada Agreement Pfizer

Another description of risks and uncertainties can be contained in Pfizer`s Business Report on Form 10-K for the year ended December 31. 2019 and the following reports on Form 10-Q, including “Risk Factors” and “Forward-Looking Information and Factors That May Future Future Results,” as well as in its subsequent reports on Form 8-K, all submitted to the U.S. Securities and Exchange Commission and available under www.sec.gov and www.pfizer.com. KIRKLAND, QC, and Mainz, Germany, August 5, 2020 /CNW/ – Pfizer Canada and BioNTech SE today announced an agreement with the Canadian government to provide their BNT162 RNAM vaccines for SARS-COV2, subject to clinical success and approval by Health Canada. This press release contains “forward-looking statements” from BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may contain information about BioNTech`s efforts to combat COVID-19, but not limited to this: the opening date of clinical trials with BNT162 and the likely publication of data from these clinical trials; The date of authorization or authorization for the use of an emergency physician; The potential for additional supply agreements with other legal systems or the COVAX facility; The potential safety and effectiveness of BNT162; BioNTech and Pfizer`s cooperation in developing a potential COVID-19 vaccine; and BioNTech`s ability to provide quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. All forward-looking statements contained in this press release are based on BioNTech`s current expectations and beliefs in future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and negatively from the results presented or implied in such forward-looking statements. These risks and uncertainties include, among other things, competition for the creation of a vaccine against COVID-19; The ability to achieve comparable clinical outcomes in larger and more diverse clinical trials; The ability to effectively develop our production capacity; and other potential difficulties. An explanation of these risks and other uncertainties can be contained in BioNTech`s Management Report on Form 20-F, submitted to the SEC on March 31, 2020 and available on the SEC`s website at www.sec.gov. All information contained in this press release refers to the date of publication and BioNTech undertakes no commitment to update this information, unless required by law. To date, the Canadian government has allocated $1 billion to the five existing agreements. These include some of the advances that pharmaceutical companies need to support vaccine development, testing and manufacturing. Financial details of the agreement were not disclosed, but conditions were based on delivery date and dose volume.

As requested by the Canadian government, vaccine deliveries are expected sometime in 2021. Financial details of the deal were not disclosed, Pfizer and BioNTech said in a joint statement, adding that conditions are based on delivery date and dose volume. Below is an overview of each company that has an agreement with the federal government, the type of vaccine in development and the number of doses reserved by Canada. Anand stated that Canada has already entered into agreements to purchase 350 million doses of COVID-19 vaccines from seven manufacturers. The number of doses could reach 414 million if the federal government makes choices with these drug manufacturers.

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Comments are closed.